Danny T. Lowe

Centamin Egypt Ltd. engages in the exploration and mining of gold. The company was founded on March 24, 1970 and is headquartered in Mount Pleasant, Australia.

Synexus Clinical Research Ltd. offers clinical trials and biological research services. It offers clinical trial management, project management, medical imaging and medical procedures. The company was founded in 1998 and is headquartered in Lancashire, the United Kingdom.

J. Rothschild Capital Management Ltd. (JRCML) is the wholly-owned investment management subsidiary of RIT Capital Partners plc in the UK. Established in 1987, the firm is based in London and provides investment management services.

El-Raghy Kriewaldt Pty Ltd. is an Australian investment services company founded in 1984. The private company is based in Perth, Australia. The company provides investment services.

Part of GSK Plc, Wellcome Plc is a British company that specializes in the discovery, development, manufacture, and sale of human healthcare products. The company is based in Greenford, UK.

Part of Canadian Imperial Bank of Commerce, CIBC Wood Gundy Australia Ltd. is an Australian mining company.

Target Group Ltd. provides software and outsourcing solutions to financial services companies. It specializes in delivering business solutions to the following markets such as loans and mortgages, investments, general insurance, and utilities and finance brokers. The company offers data analytics, data integrity, due diligence, legal title management, process optimization, shortfall debt recovery, standby servicing, customer remediation support and compliance services. Target Group was founded in 1979 and is headquartered in Cardiff, the United Kingdom.

ReNeuron Ltd. researches and develops drugs, diagnostics, and other therapeutic products. The company was founded on May 23, 1997 and is headquartered in Bridgend, the United Kingdom.

S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has received orphan drug designation from the U.S. FDA. S*BIO has entered into a development collaboration, and option & license agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize SB1518 and its other novel JAK2 inhibitor, SB1578. S*BIO's SB1317, a novel multikinase inhibitor, is in pre-clinical development and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization. In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include EDB Investments' biomedical sciences subsidiary Bio*One Capital, Aravis Ventures, Novartis Bioventures and other international funds. In 2009, S*BIO received the BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award.

The Association of the British Pharmaceutical Industry is a non-profit organization, which engages in the research and development of medicines. It focuses on biosciences. The company is headquartered in London, the United Kingdom.

IOmet Pharma Ltd. develops drugs and related products. It focuses on developing the novel ideas sourced from universities, research institutes and industry as well as internally generated programs. The company was founded by Peter Trill and Tom Brown in 2010 and is headquartered in Scotland, the United Kingdom.

Macrotarg Ltd. is a biotechnology research and British experimental development company founded in 2007. The private company is based in Winnersh, UK.

Part of Centamin Plc, Centamin West Africa Holdings Ltd. is a holding British company whose subsidiaries are engaged in mineral exploration for gold deposits. The company is based in London, UK.

Part of Neurocrine Biosciences, Inc., Diurnal Ltd. is a European, British UK-headquartered specialty pharmaceutical company founded in 2004. The company is based in Cardiff, UK. The company is dedicated to developing lifelong treatments for rare and chronic endocrine conditions.

Cannevert Therapeutics Ltd. engages in the provision of medical cannabis research. It offers sound scientific basis for the therapeutic use of cannabis that is essential to drafting rational and effective cannabis legislation. The company was founded by Michael J. A. Walker and is headquartered in Vancouver, Canada.

Monument Therapeutics Ltd. is a British UK-based biotechnology company that focuses on bringing precision medicine to neuroscience drug development. The company is based in Bottisham, UK, and was founded in 2019. The company was formed as a spin-out from Cognition and has a mission to use precision medicine to develop therapeutic products for patients with substantial central nervous system indications and significant unmet medical needs. Monument Tx has a well-balanced pipeline that includes two lead programs, and proprietary biomarkers developed by the team allow for precise selection of patients most likely to benefit from treatment. The therapeutic products under development are novel formulations utilizing well-characterized technology. Jenny Barnett has been the CEO of the company since 2019.

Imophoron Ltd. is an American company that specializes in cutting-edge vaccine development. The company's scientific advisory board consists of world-leading experts in vaccine technology and infectious diseases. The company is constantly exploring new and innovative ways to combat infection using the latest techniques from science and technology. More information about the company can be found on their website at www.imophoron.com. The company was founded by Fred Garzoni and Richard Edward Bungay has been the CEO of the company since 2022.

Reset Pharmaceuticals, Inc. is a clinical-stage biotechnology company that focuses on developing and commercializing novel treatments for patients suffering from mental illness related to life-altering diseases. Reset Pharmaceuticals is based in Great Neck, NY and was founded by Philip Taub and Jan-Anders Karlsson. The company's lead product candidate, the oral psilocybin, is being developed to treat demoralization syndrome in patients with cancer. Reset Pharma has a highly experienced team with a strong track record of successful development, approvals, and launches of neuroscience drugs. The company also has a scientific advisory board of key opinion leaders in psychiatry, oncology, and psychedelics, as well as a strategic advisory board of business leaders and financial experts.

NextPharma Technologies Holding Ltd. operates as a pharmaceutical contract development and manufacturing firm. It specializes in modified release technologies and in product manufacturing including hormones, penicillin, and cephalosporin. The company was founded on January 2, 2003 and is headquartered in London, the United Kingdom.